Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“Follow MedCity News if you want to know who is doing what in healthcare innovation - and whether it's working or not.”

Chris Seper, CEO & Founder, MedCityNews.com


Sign up for our daily newsletter


Pozen inks $75M U.S. royalty deal for Treximet with Canadian pension fund

5:54 pm by | 0 Comments

Pozen (NASDAQ:POZN) has sold the U.S. royalty rights for migraine drug Treximet to Canada’s national pension fund, CPPIB Credit Investments in a $75 million deal.

The terms of the deal give the Chapel Hill, North Carolina pharmaceutical company a 20 percent interest in any royalties received by the pension fund starting April 1, 2018, according to a filing with the Securities and Exchange Commission.

Treximet is marketed in the United States by Pozen drug partner GlaxoSmithKline (NYSE:GSK). GlaxoSmithKline holds the license to develop and market Trexmet in the United States, and Pozen has the right to develop and market a lower dose of the drug outside the country, according to Reuters. Pozen also receives royalties based on net sales of Treximet from GSK and starting in January 2010, that royalty rate more than tripled to 18 percent, according to Pozen’s website.

For the first nine months of 2011, revenues from royalties on Treximet were of $12.2 million, according to the company’s third quarter earnings report, making it the best money earner in its drug arsenal.

Advertisement

Despite the end of regulatory exclusivity for the drug in April, Pozen has successfully fought numerous companies developing generic versions of Treximet in a court case  against Par Pharmaceutical (NYSE:PRX), Alphapharm and Dr. Reddy’s Laboratories (NYSE:RDY), allowing Treximet to continue without generic competition until its patents expire; two expire in 2017 and one expires in 2025.

Pozen could not be reached for comment.

A spokeswoman for the pension fund said: “CPPIB’s acquisition of the royalty interest in Pozen Inc.’s prescription drug Treximet is part of an Intellectual Property strategy that the organization launched in 2010.  Royalty investing can provide attractive risk-adjusted returns for our fund.  To date, we have completed intellectual property transactions totaling approximately US$350 million.  We will continue to look for investment opportunities in this area.”

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Stephanie Baum

By Stephanie Baum

Stephanie Baum is the East Coast Innovation Reporter for MedCityNews.com. She enjoys covering healthcare startups across health IT, drug development and medical devices and innovations deployed to improve medical care. She graduated from Franklin & Marshall College in Pennsylvania and has worked across radio, print and video. She's written for The Christian Science Monitor, Dow Jones & Co. and United Business Media.
Visit website | More posts by Author

0 comments